Cary J. Claiborne
2023 - ADIAL PHARMACEUTICALS
In 2023, Cary J. Claiborne earned a total compensation of $801.6K as Chief Executive Officer and Member of the Board of Directors at ADIAL PHARMACEUTICALS, a 21% decrease compared to previous year.
Compensation breakdown
| Bonus | $190,000 |
|---|---|
| Option Awards | $73,314 |
| Salary | $465,625 |
| Other | $72,682 |
| Total | $801,621 |
Claiborne received $465.6K in salary, accounting for 58% of the total pay in 2023.
Claiborne also received $190K in bonus, $73.3K in option awards and $72.7K in other compensation.
Rankings
In 2023, Cary J. Claiborne's compensation ranked 1,458th out of 2,978 executives tracked by ExecPay. In other words, Claiborne earned more than 51.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,458 out of 2,978 | 51st |
Division Manufacturing | 862 out of 1,637 | 47th |
Major group Chemicals And Allied Products | 560 out of 906 | 38th |
Industry group Drugs | 544 out of 869 | 37th |
Industry Pharmaceutical Preparations | 383 out of 627 | 39th |
Source: SEC filing on September 27, 2024.
Claiborne's colleagues
We found two more compensation records of executives who worked with Cary J. Claiborne at ADIAL PHARMACEUTICALS in 2023.